This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Université de Montréal directory, so their courses may be missing. Find their university profile.
Research
Latest papers
Multidrug Interactions: Why Do They Occur and How to Handle?
Clinical therapeutics · 2023
Case Report: Performing a Medication Safety Review Assisted by Pharmacogenomics to Explain a Prescribing Cascade Resulting in a Patient Fall.
Medicina (Kaunas, Lithuania) · 2023 · senior author
Utilizing Pharmacogenomics Results to Determine Opioid Appropriateness and Improve Pain Management in a Patient with Osteoarthritis.
Pharmacogenomics and personalized medicine · 2022 · senior author
Latest funding
- $507,268
Effects of Type 2 Diabetes (T2D) on drug disposition and CYP450 activities; a special look at extra-hepatic metabolism.
CIHR · 2013 · Nominated PI
- $807,020
The first characterization of functional CYP450 activities in human cardiac myocytes: Modulation of cardiac potassium channel block due to the local metabolism of QT-prolonging drugs.
CIHR · 2011 · Co-investigator
32 publications.
Multidrug Interactions: Why Do They Occur and How to Handle?
Dow P, Michaud V, Turgeon J
Case Report: Performing a Medication Safety Review Assisted by Pharmacogenomics to Explain a Prescribing Cascade Resulting in a Patient Fall.
Russell J, Arwood MJ, Toro-Pagán NMD, Amin NS, Cambridge MD, Turgeon J, Michaud V
Utilizing Pharmacogenomics Results to Determine Opioid Appropriateness and Improve Pain Management in a Patient with Osteoarthritis.
Pizzolato K, Thacker D, Del Toro-Pagán NM, Amin NS, Hanna A, Turgeon J, Michaud V
Pharmacogenomics and Drug-Induced Phenoconversion Informed Medication Safety Review in the Management of Pain Control and Quality of Life: A Case Report.
Muhn S, Amin NS, Bardolia C, Del Toro-Pagán N, Pizzolato K, Thacker D, Turgeon J, Tomaino C, Michaud V
Illustrative and historic cases of phenoconversion.
Michaud V, Dow P, Turgeon J
Determination of CYP450 Expression Levels in the Human Small Intestine by Mass Spectrometry-Based Targeted Proteomics.
Grangeon A, Clermont V, Barama A, Gaudette F, Turgeon J, Michaud V
Quantifying Anticholinergic Burden and Sedative Load in Older Adults with Polypharmacy: A Systematic Review of Risk Scales and Models.
Al Rihani SB, Deodhar M, Darakjian LI, Dow P, Smith MK, Bikmetov R, Turgeon J, Michaud V
Adverse drug event risk assessment by the virtual addition of COVID-19 repurposed drugs to Medicare and commercially insured patients' drug regimens: A drug safety simulation study.
Smith MK, Bikmetov R, Al Rihani SB, Deodhar M, Hafermann M, Dow P, Turgeon J, Michaud V
Tabula Rasa HealthCare company profile: involvement in pharmacogenomic and personalized medicine research.
Matos A, Dow P, Bingham JM, Michaud V, Lesko LJ, Knowlton CH, Turgeon J
Chronic Inflammatory Status Observed in Patients with Type 2 Diabetes Induces Modulation of Cytochrome P450 Expression and Activity.
Darakjian L, Deodhar M, Turgeon J, Michaud V
Effects of Type 2 Diabetes (T2D) on drug disposition and CYP450 activities; a special look at extra-hepatic metabolism.
Principal investigators: Michaud, Véronique
Keywords: Cytochromes P450; Drug Analysis; Drug Metabolism; Lc-Ms/Ms; Molecular Biology; Pharmacogenetics; Pharmacokinetics; Phenotype; Type 2 Diabetes
The first characterization of functional CYP450 activities in human cardiac myocytes: Modulation of cardiac potassium channel block due to the local metabolism of QT-prolonging drugs.
Principal investigators: Turgeon, Jacques
Keywords: Cardiac Electrophysiology; Cytochromes P450; Drug Metabolism; Heart; Human; Potassium Channels; Qt-Prolonging Drugs
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.